Abstract
The aryl hydrocarbon receptor (AHR) is believed to mediate many of the toxic, carcinogenic, and teratogenic effects of environmental contaminants such as dioxins, polycyclic aromatic hydrocarbons, and polyhalogenated biphenyls. Ligands for the AHR have been shown to influence cell proliferation, differentiation, and apoptosis, but the mechanism by which the AHR affects the cell cycle is not known. Increased levels of mature transforming growth factor-β (TGFβ) has been correlated with reduced cell proliferation and increased rates of apoptosis and fibrosis. Based on the increase in portal fibrosis and small liver size observed in AHR-null (Ahr−/− ) mice, the relationship between TGFβ expression and apoptosis in this mouse line was analyzed. Livers from Ahr−/− mice had marked increase in active TGFβ1 and TGFβ3 proteins and elevated numbers of hepatocytes undergoing apoptosis compared with wild-type mice. Furthermore, increases in TGFβ and apoptotic cells were found in the portal areas of the liver, where fibrosis is found in theAhr−/− mice. In vitro, primary hepatocyte cultures from Ahr−/− mice exhibited a high number of cells in later stages of apoptosis and an elevated secretion of active TGFβ into the media compared with cultures from wild-type mice, which have previously been shown to secrete only latent forms of the molecule. Conditioned media fromAhr−/− hepatocytes stimulated apoptosis in cultured hepatocytes from wild-type mice. Taken together, these findings suggest that the phenotypic abnormalities inAhr−/− mice could be mediated in part by abnormal levels of active TGFβ and altered cell cycle control.
Footnotes
- Received February 17, 1998.
- Accepted April 23, 1998.
-
Send reprint requests to: Dr. Frank J. Gonzalez, NCI/NIH, Bldg. 37, Rm. 3E-24, Bethesda, MD 20892. E-mail: fjgonz{at}helix.nih.gov
-
↵1 Current affiliation: Laboratorio de Bioquı́mica y Biologı́a Molecular, Facultad de Ciencias, Universidad de Extremadura, 06080-Badajoz, Spain.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|